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Abstract
Background: Cardiovascular diseases (CVD) are a leading contributor to the burden of disease in low- and middle-
income countries. Guidelines for CVD prevention care in low resource settings have been developed but little
information is available on strategies to implement this care. A community health insurance program might be
used to improve patients’ access to care. The operational research project “QUality Improvement Cardiovascular
care Kwara - I (QUICK-I)” aims to assess the feasibility of CVD prevention care in rural Nigeria, according to
international guidelines, in the context of a community based health insurance scheme.
Methods/Design: Design: prospective observational hospital based cohort study.
Setting: a primary health care centre in rural Nigeria.
Study population: 300 patients at risk for development of CVD (patients with hypertension, diabetes, renal disease
or established CVD) who are enrolled in the Hygeia Community Health Plan.
Measurements: demographic and socio- economic data, physical and laboratory examination, CVD risk profile
including screening for target organ damage. Measurements will be done at 3 month intervals during 1 year.
Direct and indirect costs of CVD prevention care will be estimated.
Outcomes: 1) The adjusted cardiovascular quality of care indicator scores based on the “United Kingdom National
Health Services Quality and Outcome Framework”. 2) The average costs of CVD prevention and treatment per
patient per year for patients, the clinic and the insurance company. 3) The estimated net health care costs of
standard CVD prevention care per quality-adjusted life year gained.
Analysis: The primary outcomes, the score on CVD quality indicators and cost data will be descriptive. The quality
scores and cost data will be used to describe the feasibility of CVD prevention care according to international
guidelines. A cost-effectiveness analysis will be done using a Markov model.
Discussion: Results of QUICK-I can be used by policy makers and professionals who aim to implement CVD
prevention programs in settings with limited resources. The context of the insurance program will provide insight
in the opportunities community health insurance may offer to attain sustainable chronic disease management
programs in low resource settings.
Trial registration: This protocol has been registered at ISRCTN, ID number: ISRCTN47894401.
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Cardiovascular diseases (CVD) are well established as a
leading contributor to the burden of disease in low-
income and middle-income countries (LMIC). Over 80%
of global CVD mortality occurs in LMIC [1]. The bur-
den of non-communicable diseases in LMIC is likely to
increase substantially over the next decades, and will
become one of the most important causes of death and
disability, because of the expected health and demo-
graphic transition [2,3]. CVD in sub-Saharan Africa
(SSA) has a large economic impact, with an estimated
financial burden of tens of billions of US dollars over
the next decade [4,5]. Interventions to prevent CVD,
such as multidrug regimes for high risk individuals, are
available and were found cost effective in LMIC in mod-
elling studies [6,7] but coverage in these settings is low
[8].
The need for control of non communicable diseases
and implementation of CVD prevention programs in
LMIC was recently emphasized [9-14]. The World
Health Organization and the International Society of
Hypertension (WHO/ISH) have jointly published guide-
lines for the treatment of CVD risk factors in LMIC
[15-17]. However, implementation of CVD prevention
programs poses several challenges. The most important
is that health care for chronic diseases requires a greater
level of organization of care that must be sustained over
a longer period of time (usually a patients’ lifetime) than
care for acute problems. In addition, access to health
care, in particular affordability of drugs and travel, can
pose restraint on the prospective patients. This was
demonstrated in the USA where limited access to care
due to lack of insurance, was associated with increased
levels of forgone health care [18]. Therefore, it was
recently argued that interventions for CVD prevention
in LMIC must be logistically and financially feasible and
that operational research of implementation programs is
urgently needed [19]. In this paper, we present an
operational research project to assess the feasibility of
standard CVD prevention care according to interna-
tional guidelines in rural Nigeria, in the context of a
subsidized, community based health insurance program.
The insurance program: Health Insurance Fund
Fifty percent of SSA’s total health expenditure is
financed by out of pocket payments, causing many to
fall into a poverty trap having to pay for healthcare ser-
vices [20,21]. The Health Insurance Fund (HIF) is an
international not-for-profit organization committed to
t h ed e l i v e r yo fa f f o r d a b l eq u a lity private health insur-
ance and healthcare services for low-and middle-income
families. The mission of the HIF program is to protect
the wealth of low- and middle- income families from
health-related risks, so that families can lead lives of
self-reliance, and meet their basic needs. To achieve this
mission the HIF program is building a healthcare finan-
cing and delivery system that is centred around private
health insurance.
The Health Insurance Fund in Nigeria
The first two HIF programs started in early 2007 in
N i g e r i ai nL a g o sa n dK w a r aS t a t eu n d e rt h en a m eo f
Hygeia Community Health Plan (HCHP). The imple-
mentation of the HIF program in Nigeria is carried out
by PharmAccess Foundation and the local Health Main-
tenance Organization Hygeia Nigeria Ltd. Hygeia has
contracted both private and public clinics to provide the
care for the enrolees. The HCHP program provides
access to care for patients, performs upgrading of all
clinics participating in the program, implements guide-
lines, assists the health care providers in improving
financial and administrative management in the clinic
and monitors and evaluates these processes. The insur-
ance package provides coverage for the most common
medical problems found among the target groups and
consists of primary care, and limited secondary care
(limited hospitalization and basic surgery). A more
detailed description of the insurance program can be
found at HIF’s website [22].
Treatment for CVD risk factors such as hypertension
and diabetes is included in the insurance package.
Before the start of the HCHP program, guidelines for
CVD prevention care were not available and very few
patients were treated for CVD risk factors. As part of
the HCHP program, staff was trained in CVD risk man-
agement including treatment guidelines (see Additional
file 1) and other relevant topics, such as ECG reading.
Aim of the study
It is hypothesized that the HCHP program can be used
to provide high quality CVD prevention care according
to international guidelines by covering the costs of the
CVD prevention care (access to care). The project
QUality Improvement Cardiovascular care Kwara-I
(QUICK-I) aims to assess the feasibility of standard
CVD prevention care according to international guide-
lines, in a low resource setting, in the context of the
HCHP health insurance scheme. Both operational feasi-
bility of CVD care in the clinic (e.g. availability of
laboratory tests, drugs, doctors) and financial feasibility
(for the insurer, the clinic and the patients) will be eval-
uated. Operational feasibility will be assessed by measur-
ing the quality of CVD prevention care in the study
clinic after the implementation of the CVD prevention
program. Financial feasibility will be assessed by estimat-
ing the costs of the CVD prevention program. Figure 1
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the HCHP program. In addition, patient-related deter-
minants of feasibility, focused on patient education and
drug adherence, will be studied simultaneously, and is
described elsewhere [23].
Methods
Project Design
This is a prospective observational hospital based cohort
study.
Setting
Study clinic
The clinic participating in this project is Ogo Oluwa
Hospital (OOH) in Bacita (Kwara State), a private clinic
in rural Nigeria that participates in the HCHP program.
The hospital has admission capability and operates very
busy weekly primary care clinics for the management of
CVD prevention care. At most times, at least 3 doctors,
6 nurses, 3 laboratory staff, 3 records staff, 2 pharmacy
staff, 2 administrative staff and several other support
staff are available during service hours. At the time of
writing, 9500 patients enrolled in the HCHP program,
were registered in OOH. As almost all patients consult-
ing OOH are enrolled in the HCHP program, this num-
ber can be considered an estimate of the total patient
population registered in OOH.
Population
OOH provides care for the people who live in the area
around the community of Bacita. This population is a
rural, low income, farming community, predominantly
Muslim and belongs mostly to the Nupe and Yoruba
ethnic groups. Bacita is 1 of the 4 most populous com-
munities in Edu Local Government Area. Edu has an
estimated population size of 201,469 [24].
Inclusion and exclusion criteria
Table 1 shows the inclusion and exclusion criteria of the
study. In order to be included a patient needs to meet
all inclusion criteria and none of the exclusion criteria.
Patients who do not meet the inclusion criteria or who
meet one of the exclusion criteria will receive the same
Figure 1 General outline of QUality Improvement Cardiovascular care Kwara-I (QUICK-I) within the Hygeia Community Health Plan.
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the cohort.
Project Duration
The inclusion of patients in the cohort is expected to
take 6 months. Each patient will be followed for 1 year.
Total duration of data collection is therefore estimated
to be 18 months. After the project has finished, CVD
prevention care will be continued according to the
implemented guidelines.
Investigations and Follow up
Patients who are included in the project will be assessed
every 12 months according to current CVD prevention
guidelines [15-17,25-27]. In addition, regular follow up
visits will take place with the doctors according to local
practice of care (usually patients are seen by the doctors
once a month). In addition, for study purposes, patients
are seen every 3 months during 1 year by a dedicated
nurse who assists in data collection. The data collected
during each visit are shown in Table 2.
Patients will be reminded of their upcoming study vis-
its using telephone calls or text messages. Patients, who
do not show up for study visits, will be contacted (if
needed by home visit) by a study staff member to inves-
tigate the reasons for no show. Rates of loss to follow
up and reasons for no show will be described as part of
the feasibility of CVD prevention care.
Primary Endpoints
The primary endpoints of QUICK-I are:
A. The adjusted cardiovascular care quality scores
based on the United Kingdom National Health Services
Quality and Outcome framework (NHS QOF) [28]
after the implementation of the CVD prevention pro-
gram. The score will be measured after the last patient
has completed follow up (estimated 1.5 years after
baseline). The quality indicators are shown in Addi-
tional file 2.
B. The range of possible costs of CVD prevention
treatment per patient per year, divided per category
(treatment, consultation etc). Pre-specified subgroup
analysis will include costs for the insurance company
considering the current and alternative benefit packages,
the hospital, and the patient.
C. The estimated net health care costs of standard
CVD prevention care per quality-adjusted life year
(QALY) gained in a community health insurance setting.
Secondary Endpoints
Secondary endpoints for QUICK-I are shown in table 3.
Secondary endpoints will be analyzed for responders
and non-responders to treatment, as defined in Table 4.
Definitions of clinical outcomes
A patient is considered to be successfully treated if there
is a significant improvement in any of the risk factors
that were present before the start of the prevention
Table 2 Data collection and investigations during each
study visit
Month 0 3 6 9 12
Demographic data X
Socioeconomic data X
Co morbidities X
Cardiovascular risk factors X X X
Transport costs X X X X X
Drug use for cardiovascular disease (prevention)
and side effects
XXXX X
Morisky adherence questionnaire [40] X X X X X
Rose angina pectoris questionnaire [41,42] X
Quality of life using the 12-Item Short Form Health
Survey (SF-12) [43]
XX
Health care utilization and health care expenditures X X X X
Cardiovascular events X X X X
Physical Examination (height, weight, hip and waist
circumference, blood pressure, heart rate)
XXXX X
Blood tests: (potassium, creatinine, lipid profile) X X
Blood tests: glucose X X* X* X* X
Urine tests (microalbuminuria, proteinuria**) X X
Electrocardiogram X X
*Only for diabetic patients.
** Only if microalbuminuria test result is out of range at upper measuring
range.
Table 1 Inclusion and exclusion criteria for QUality
Improvement Cardiovascular care Kwara-I
Inclusion
criteria
1. ≥ 18 years of age
2. Visiting the outpatient clinic/admitted to the clinic
3. Enrolled in the Hygeia Community Health Plan
4. At least one of the following:
a. diagnosis of hypertension
b. diagnosis of diabetes mellitus
c. established cardiovascular disease (stroke,
myocardial infarction, angina pectoris)
d. diagnosis of renal disease
Exclusion
criteria
1. Patients who are unwilling to provide consent for
data collection
2. All pregnant or lactating females
3. All patients with suspected secondary
hypertension
4. Any person who is incapable of giving informed
consent
5. Patients who are not permanently residing in
Kwara State*
*Patients who are not permanently residing in Kwara State are not eligible for
the HCHP program.
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vidual endpoint. The definitions of significant improve-
ment are shown in table 4.
Sample size
The main objective of this study is to describe the cardi-
ovascular care performance of the clinic using quality
indicators. Sample size calculations for quality indicator
scoring are difficult because the number of cases used
to score an indicator depends on the prevalence rate of
each condition of interest in the clinic where scoring
takes place. Therefore, composite scores, based on
pooled indicators of one disease category, are considered
better indicators than individual indicator scores [29]. In
a study that assessed the feasibility of quality indicator
assessment for multiple conditions in general practice,
sample sizes of 7-12 patients for each of the conditions
were required to achieve 90% confidence intervals of +/-
10 points on estimated pass rates (the number of cases
for which the indicator was passed) for composite scores
per disease category [29].
T h es e c o n d a r yo u t c o m eo ft h i sp r o j e c ti st h ep r o p o r -
tion of subjects that are successfully treated. In a com-
munity based survey in Mozambique, 40% of the
participants on treatment for hypertension were found
to have a blood pressure at target level [30]. Assuming
30% of patients will be treated successfully, 300 patients
will provide sufficiently narrow confidence limits around
the estimate (95% CI: 24.9% -35.5%). The study sample
size of 300 patients is therefore based on the secondary
outcome and will also allow scoring of quality indicators
(primary outcome).
A subgroup analysis will be performed on patients
who are newly diagnosed or who have not received
treatment for at least 1 year ("new” patients), and
patients who were identified and put on treatment prior
to inclusion into the QUICK-I study.
We aim to enrol 150 new and 150 patients already on
treatment (20% success: 95% CI: 13.9% -27.3%; 30% suc-
cess: 95% CI 22.8%-38.0) within 6 months. Evaluation of
the feasibility to reach the sample size and the distribu-
tion across the two subgroups, will take place 3 months
after the start of inclusion. A minimum sample size of
100 patients in each of the subgroups will be required.
Statistical Methods
Primary outcome
The primary outcome is a descriptive analysis of the
quality scores using the NHS QOF indicators, adjusted
to the local context, after initiation of standardized CVD
management. Only disease domains relevant to CVD
will be used (primary prevention, hypertension, diabetes,
heart failure, stroke, chronic kidney disease, obesity and
smoking). Scoring methods are summarized in Addi-
tional file 2. The score will be used to assess the feasibil-
ity of CVD prevention care according to the WHO/ISH
Table 4 Definitions of significant improvement per risk
factor
Risk factor Significant improvement
Blood pressure Blood pressure at target level:
Patients without diabetes or established
cardiovascular disease (CVD): < 140 mmHg
systolic and < 90 mmHg diastolic.
Patients with diabetes, renal disease or establish
CVD: < 130 mm Hg systolic and 80 mmHg
diastolic.
For those who do not reach target levels:
blood pressure decrease of > 10% systolic or
diastolic
Dyslipidemia Lipid profile at target level:
Primary prevention: total cholesterol (TC) < 5.0
mmol/L and low density lipoprotein (LDL)
cholesterol < 3.0 mmol/l.
Secondary prevention: TC < 4.0 mmol/L and
LDL cholesterol < 2.5 mmol/l.
For those who do not reach target levels:
reduction in total cholesterol ≥ 25% or LDL ≥
30% (whichever is greater).
Diabetes Fasting plasma glucose < 7.0 mmol/l
Random plasma glucose of < 12 mmol/l
Abdominal Obesity Reduction of waist circumference to ≤ 102 cm
(M), ≤ 88 cm (F)
Left Ventricular
Hypertrophy (LVH)
Regression of LVH (electrocardiogram based)
according to Sokolov-Lyon criteria [44]
Microalbuminuria Disappearance of microalbuminuria (< 30 mg/
ml in spot morning urine)
Proteinuria Disappearance of proteinuria (negative
quantitative dipstick)
Renal impairment Improvement in creatinine clearance to a new
estimated glomerular filtration rate class [45]
after treatment.
Smoking Quit smoking
Table 3 Secondary endpoints for QUICK-I
Secondary Endpoints QUICK-I
1. The proportion of patients in whom cardiovascular disease (CVD)
risk factor treatment is successful (see definitions) after 1 year of
follow up
2. The incidence of target organ damage* and established CVD
during the study period
3. The incidence of all cause mortality during the study period
4. Change in the score on the 12-Item Short Form Health Survey
quality of life questionnaire at 1 year of follow up compared to
baseline
5. Change in the score on the 8-item Morisky Medication
Adherence Scale measured with 3 month intervals during one year
of follow up
6. Incidence of side effects of prescribed drugs for CVD prevention,
during the follow up period
*Target organ damage: presence of micro/macroalbuminuria or ECG based left
ventricular hypertrophy.
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scores of individual NHS QOF indicators. For example,
t h eg u i d e l i n et op e r f o r maC V Dr i s ka s s e s s m e n ti na l l
patients with hypertension will be assessed on the basis
of the scores of indicator primary prevention 1: “patient
newly diagnosed with hypertension had a face to face
cardiovascular risk assessment at the outset of diagnosis
using an agreed risk assessment tool.” The NHS QOF
indicators are used in primary health care centres in the
UK. The score of the study clinic will also be compared
with scores of primary health care practices in the UK.
Designated patient files for CVD prevention care were
introduced in the clinic prior to the start of the study.
These files serve as the source for scoring of quality
indicators of patient care provided for the study popula-
tion included in QUICK- I.
Costs and cost-effectiveness analysis
Descriptive statistics will be applied to calculate costs of
the CVD prevention program for the clinic, the patients
and the insurance company. Estimation of the impact of
CVD prevention care on total medical pay out of the
insurance company will be done using a mathematical
model. Prevalence data of patients at risk for CVD in
the insured population will be used as input in this
model. Scenario analysis will then be performed to esti-
mate the cost impact for the insurer of different treat-
ment thresholds (e.g. low versus high risk) and with
different benefit packages.
Cost effectiveness of standard CVD prevention care in
this low resource setting will be estimated using a Mar-
kov model with varying probabilities of disease events
and mortality to assess the benefits, risks, and costs of
the treatment regimes for low, moderate and high CVD
risk. Since the analysis will use at least a 10-year time
horizon, the long-term effectiveness and cost-effective-
ness will be based not only on the QUICK-1 cohort
study data, but also on Framingham risk functions
(using baseline and follow-up data), relative risk reduc-
tions expected from treatment, background mortality
rates, and costs of CVD events. Outcomes in the ana-
lyses will be measured in QALYs gained and net health-
care costs. Multivariate sensitivity analysis will be per-
formed for all variables with a pre-specified range of
uncertainty with Monte Carlo simulation.
Secondary outcomes
The proportion of patients in whom treatment is suc-
cessful at 1 year of follow up will be determined for the
entire cohort. Individuals who achieved the target will
be compared with those who did not and analyzed for
explanatory variables using multivariate logistic regres-
sion analyses. The proportion of patients who reached
treatment target goals will also be determined for each
risk factor separately and analyzed using multivariate
logistic regression, if sample size allows. The prevalence
and incidence of TOD, CVD and mortality with confi-
dence intervals will be determined. Multivariate analyses
will be used to adjust for known or suspected confound-
ing variables. Descriptive statistics will be applied for
quality of life, side effects of medication and adherence
to therapy. Individuals who are adherent to therapy will
be compared with non-adherent individuals and ana-
lyzed for explanatory variables using multivariate logistic
regression analyses.
Ethical Approval
The QUICK studies will be performed following Good
Clinical Practice guidelines and complying with the
Declaration of Helsinki principles. Ethical clearance has
been obtained from the institutional review board of the
University of Ilorin Teaching Hospital (Ref: UITH/CAT/
189/13/13, dated 30
th March, 2010), Kwara State,
Nigeria.
Start Date & Time Lines
Patient inclusion started in June 2010 and the last
patient is expected to complete follow up in December
2011.
Discussion
Guidelines for CVD care in LMIC have been developed
[15-17] but little evidence-based information is available
on strategies for effective and successful implementation
of such care in settings with low resources. Community
health insurance programs have been put forward as a
means to improve patient access to healthcare but
operational difficulties still hamper the successful devel-
opment of community health insurance schemes [31].
The context of the insurance program makes this pro-
ject unique. By removing the barrier of patient out of
pocket expenditures through an insurance program, the
project can evaluate health effects of the interventions
in the program and identify limiting factors for imple-
mentation of CVD prevention care. Results of such
operational research can be used in future program
designs. This project could serve as a model for policy
makers and professionals who aim to implement CVD
prevention programs in settings with limited resources.
The feasibility of hypertension and diabetes treatment
in primary health care in SSA has been assessed in a
limited number of studies [32-35]. These studies
demonstrate improvements in blood pressure, glucose
or HbA1c levels using simple treatment protocols
(usually applied by dedicated study nurses). We have
chosen for quality indicators as the primary outcome
instead of risk factor control. This will give a better
insight in which components of CVD care are feasible
and which are not when implementing CVD prevention
care according to international guidelines, using the
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ever, risk factor reduction after implementation of the
CVD program will be described as a secondary outcome.
The NHS QOF indicators are developed in the United
Kingdom. There is no CVD prevention quality indicator
set developed specifically for low resource settings.
WHO/ISH has developed guidelines for the prevention
of CVD in LMIC but there are no tools available to mea-
sure adherence to these guidelines. In addition, experts
disagree which quality indicators are relevant to measure
quality of care for primary prevention of CVD [36]. We
have chosen the NHS QOF indicators because they have
been developed to assess the quality of care in primary
health care settings and because the indicators are based
on international guidelines. We will describe the results
in the context of international CVD prevention guide-
lines such as the WHO/ISH guidelines [15-17]. Some of
the QOF NHS indicators refer to services that are not
available in a rural low income setting. We tried to adapt
these indicators to the local context wherever possible
(for example by replacing the need for an HbA1c test in
diabetic patients with a blood glucose test). Other indica-
tors that refer to unavailable services (such as influenza
vaccinations for diabetic patients) will fall under the
exception reporting criteria. More information on the
scoring systems and exception reporting can be found in
Additional file 2 and at the QOF NHS website [28].
Previous studies in SSA have focussed on either
hypertension or diabetes care [32-35]. We have chosen
to include all patients who are at high risk to develop
CVD, independent of whether they have hypertension,
diabetes or other CVD risk factors. This heterogeneity
makes our study population representative of the popu-
lation which doctors in SSA encounter in their clinics.
This approach is in line with WHO recommendations
to focus on total CVD risk instead of a single risk factor
approach [16].
The financial aspects of delivering CVD care for
patients, clinics and third parties (such as insurers) were
not addressed in recently published studies [32-35].
However, the cost of care is a major determinant of
long term sustainability of CVD prevention programs in
SSA. Therefore, the cost of the CVD prevention pro-
gram is a primary outcome in this study.
Our study population is enrolled in the HCHP pro-
gram so the study describes the feasibility of CVD pre-
vention care in the context of this insurance program.
As the majority of the population in Kwara State is eligi-
ble for this insurance program and enrolment rates are
high, the results of our study will be applicable to the
Kwara population in general. Currently, the insurance
program is operational in 2 out of the 3 senatorial dis-
tricts of Kwara State, expansion to the third area is in
preparation. In addition, HIF started a similar program
in Tanzania, and a program in Kenya is in preparation.
There is increasing advocacy for community-based
health insurance schemes as part of a broader solution
to health care financing problems in low-income coun-
tries [37]. Recently, more community based health
insurance schemes have been planned or implemented
in SSA [38,39]. Several outcomes of our study, such as
the costs of CVD prevention for the clinic, incidence of
TOD and travel costs for patients will be relevant for
other settings, regardless of whether or not health insur-
ance is available there.
In conclusion, the results of QUICK-I can be used to
develop implementation strategies for CVD prevention
programs in settings with limited resources. The context
of the insurance program will provide insight in the
opportunities community health insurance may offer to
attain sustainable chronic disease management programs
in low resource settings.
Additional material
Additional file 1: Appendix 1: Treatment flowcharts.
Additional file 2: Appendix 2: Quality indicators.
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